CTIS2022-502155-65-00招募中1 期
HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial. CAESAR - 69HCL21_1054
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •at least 18 years of age, non severe sarcoidosis-related non-severe ENT involvement requiring systemic treatment, •pathologically proven sarcoidosis as defined by the ATS/ERS/WASOG criteria (the non-severe / severe criteria are defined in Appendix 9 of the protocol), patient able to give free, informed and written consent, affiliated to National French social security system, nons evere ocular sarcoidosis requiring systemic treatment, non severe skin sarcoidosis requiring systemic treatment, non severe osseous sarcoidosis requiring systemic treatment, non severe sarcoidosis with joint involvement requiring systemic treatment, non severe sarcoidosis-related hypercalcemia requiring systemic treatment, non severe peripheral nervous system sarcoidosis requiring systemic treatment
排除标准
- •severe sarcoidosis involvement requiring another immunosuppressant or anti-TNF antibody or methylprednisolone i.v. pulses, patient participating in other interventional research, persons under court protection, previous (<3 months before screening) or concurrent treatment with immunosuppressants, previous treatment with antimalarial drugs (HCQ/CQ), treatment with citalopram, escitalopram, hydroxyzin, domperidone and piperaquine, known hypersensitivity or intoloerance to HCQ/CQ or 4-aminoquinoline derivatives and prednisone, history of drug induced maculopathy, heart rhythm disorders on EKG (QT prolongation), severe ophthalmological impairment or ophthalmological impairment that does not allow ophthalmic monitoring; previous history of maculopathy or retinopathy, end-stage lung, liver, cardiac, or renal disease, sarcoidosis with central nervous system involvement, •women must not be pregnant, breastfeeding, or considering pregnancy during the study or within 30 days of the last study drug administration. (Contraception is considered effective when it consists of one of the following: use of a male condom during all sexual activity and/or efficient oral hormonal contraception (better considered combined contraception) and/or an intrauterine device (IUD) and/or hormone-releasing intrauterine system (IUS) and/or history of bilateral tubal ligation and/or history of vasectomy, provided the male partner is the trial participant's only sexual partner and/or sexual abstinence), cardiac sarcoidosis, clinical evidence of active infection (including infection with herpes virus and varicella-zoster virus) or severe/unstabilized comorbidity (e.g. moderate to severe heart failure) or unstabilized psychosis, chronic viral (HIV or HBV) infection, untreated latent/active tuberculosis, pregnancy or lactation (ßHCG will be test by blood analysis at inclusion), concurrent vaccination with live vaccines during therapy, inability to understand information about the protocol and to sign informed consent or not suitable candidate to comply with the requirements of this study
研究者
相似试验
进行中（未招募）
不适用
Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSASPulmonary SarcoidosisEUCTR2008-001340-39-ITIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
已完成
3 期
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).Pulmonary SarcoidosisNCT02200146University of Milano Bicocca94
进行中（未招募）
1 期
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)Profliaxis of SARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001441-39-ITIVERSITY OF OXFORD40,000
进行中（未招募）
1 期
Chloroquine/ hydroxychloroquine prevention of COVID-19 (COPCOV)EUCTR2020-001441-39-GBniversity of Oxford10,000
已完成
3 期
The prophylactic effect of Hydroxychloroquine on Novel Corona virusIRCT20151222025660N2Arak University of Medical Sciences90